IBI343 (CLDN18.2 ADC III multiregional clinical study (MRCT for gastric cancer in China and Japan. The Phase I clinical
MRCT study of pancreatic cancer has shown positive efficacy and safety signals in the Chinese
population, and has initiat partial clinical enrollment b2b email list in the Unit States. It is expect that international
key clinical studies will be initiat in 2025 after the PoC verification data is read out.
IBI363: As the world’s firstinclass (FIC PD1IL2α dualantibody drug, it has read out positive Phase I
clinical data in hundrs of core tumor types such as IOresistant lung cancer, melanoma, and
IOunresponsive “cold tumor” colorectal cancer, demonstrating its potential as a nextgeneration IO
cornerstone drug. The company is continuing to follow up on the Phase IbII expansion clinical studies
of these cancer types. Bas on PoC data and regulatory communication feback, it is expect to take the
lead in launching key registration clinical studies in China in 2025 for IOnaïve advanc melanoma and
IOresistant advanc squamous cell lung carcinoma.
At the same time
Phase II clinical studies in the Unit States are underway, and will further expand the research cohorts in lung cancer, colorectal cancer and melanoma.
At the same time, the company is accelerating global innovation through external cooperation. At the
beginning of 2025, it reach a global exclusive licensing a swipe file is essentially agreement with Roche with a total amount of
over US$1 billion. By combining Roche’s strong capabilities in global R&D, production and
commercialization, the company will accelerate the development of IBI3009 (potential bestinclass
DLL3 ADC to benefit small cell lung cancer patients around the world.
Looking ahead to 2025 , highpotential drugs will seize the opportunity
Looking ahead to 2025, the company expects it to trust review be a year of momentum and potential.
The company expects continu rapid growth in performance, innovation and breakthroughs, the launch
of 6 new drug products, and the commercialization of oncology and comprehensive product pipelines to
go hand in hand. At the same time, it further improves marketing efficiency and output, especially IBI343 (CLDN18.2 ADC.